Compare Northrop Grumman Corporation (NOC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs GeneDx Holdings Corp — how do they compare? Northrop Grumman Corporation trades at $480.72 (market cap $68.83B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Northrop Grumman Corporation is far larger — about 34.1× GeneDx Holdings Corp's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and GeneDx Holdings Corp for 19 Days on average.
| NOC | WGS | |
|---|---|---|
Market Cap | $68.83B | $2.02B |
Volume | 1,081,989 | 734,640 |
Sector | Industrials | Health |
52-Week High | $768.02 | $167.51 |
52-Week Low | $473.46 | $34.51 |
Typical Hold Time | 81 Days | 19 Days |
Enterprise Value | $82.81B | $2.05B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $484.48, up 2.33% today, but technical indicators signal a bearish trend with the stock below key moving averages. Fundamentally, the company shows strength with a P/E of 15.4, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights a mixed environment, including a significant contract loss to Boeing but sustained demand from defense budgets and a record backlog supporting future revenue.
The outlook remains positive due to strong fundamentals and analyst consensus, with a price target of $600.62 implying substantial upside. Key risks include competitive pressures from recent contract losses and dependence on government spending, but the company's financial health and dividend payments provide stability for investors.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
